# A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas

> **NCT03218072** · PHASE1 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 12 (actual)

## Conditions studied

- B-cell Lymphomas

## Interventions

- **DRUG:** HLX01

## Key facts

- **NCT ID:** NCT03218072
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-04
- **Primary completion:** 2015-01-31
- **Final completion:** 2015-01-31
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03218072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03218072, "A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03218072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*